GREAT POINT PARTNERS LLC
Q4 2024 Form 13-F
GREENWICH, CONNECTICUT
CIK 0001281446
· CRD 158423
· SEC-registered investment adviser
Consolidated report · includes
2 managers
since Q3 2013
$212.2M Reported Value Total
GREAT POINT PARTNERS, LLC reports 20 total accounts under management (AUM). There are 20 discretionary accounts valued at $1,988,112,264, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
38 funds
· $2.0B gross asset value
Private Equity Fund: $1.4B · Hedge Fund: $564.4M
Source: Form ADV filed 2026-03-31
Reported value
$212.2M
Quarter over quarter
-20.3%
Holdings
26
Top-10 concentration
61.6%
Filing Structure
Reports holdings for
- JAY JEFFREY R · File #028-12517 · since Q3 2013
- Nordahl Lillian (not a 13F filer in our records) · File #028-24470 · since Q3 2024
- Yehudai Ortav · File #028-20398 · Q3 2020 – Q2 2024
- KROIN DAVID (not a 13F filer in our records) · File #028-13262 · Q3 2013 – Q2 2020
Holdings reported by
- JAY JEFFREY R · Q2 2013 – Q2 2013 · declared by one filing
Key People
Form ADV owners & control persons
Jeffrey Robert Jay
ELECTED MANAGER, MEMBER AND MANAGING DIRECTOR
Adam Brian Felsenthal
GENERAL COUNSEL AND CHIEF COMPLIANCE OFFICER
Ronald Marc Panzier
CHIEF OPERATING OFFICER AND CHIEF FINANCIAL OFFICER
Filing Navigation
Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.
13F Metrics
Loading 13F Metrics
Q4 2024 13F record
Q4 2024 13F filing summary
| Period of report | December 31, 2024 |
|---|---|
| Filed | February 14, 2025 |
| Form | 13F-HR |
| Reported value | $212.2M |
| Positions | 26 |
| Change in reported value | -37.5% |
| New positions | 5 |
| Exited positions | 8 |
| Position turnover | 38.2% |
| Top-10 concentration | 61.6% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
41 | $418.5M |
|
Q2 2026 13F
Filed Aug 14, 2026
|
37 | $529.1M |
|
Q1 2026 13F
Filed May 15, 2026
|
39 | $435.1M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
29 | $308.4M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
28 | $242.5M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
26 | $153.8M |
|
Q1 2025 13F
Filed May 15, 2025
|
31 | $188.8M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
26 | $212.2M |
|
Q3 2024 13F
Filed Nov 13, 2024
|
29 | $339.8M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
33 | $522.0M |
|
Q1 2024 13F
Filed May 15, 2024
|
35 | $641.6M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
34 | $586.7M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
39 | $549.0M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
36 | $510.8M |
|
Q1 2023 13F
Filed May 15, 2023
|
42 | $509.3M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
40 | $510.2M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
40 | $415.3M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
33 | $417.0M |
|
Q1 2022 13F
Filed May 16, 2022
|
29 | $413.8M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
35 | $450.1M |
33 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q4 2024
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | IONS IONIS PHARMACEUTICALS INC | $17.7M | 8.32% |
| 2 | CYTK CYTOKINETICS INC | $16.9M | 7.98% |
| 3 | KALV KALVISTA PHARMACEUTICALS INC | $15.1M | 7.13% |
| 4 | VRDN VIRIDIAN THERAPEUTICS INC | $14.4M | 6.78% |
| 5 | PLRX PLIANT THERAPEUTICS INC | $13.9M | 6.55% |
| 6 | ABVX ABIVAX SA | $12.1M | 5.69% |
| 7 | DVAX DYNAVAX TECHNOLOGIES CORP | $11.0M | 5.18% |
| 8 | NGNE NEUROGENE INC | $10.1M | 4.77% |
| 9 | EOLS EVOLUS INC | $9.9M | 4.66% |
| 10 | XENE XENON PHARMACEUTICALS INC | $9.6M | 4.53% |
| 11 | UNCY UNICYCIVE THERAPEUTICS INC | $8.7M | 4.11% |
| 12 | ZURA ZURA BIO LTD | $7.9M | 3.73% |
| 13 | AUTL AUTOLUS THERAPEUTICS PLC | $7.1M | 3.33% |
| 14 | JSPR JASPER THERAPEUTICS INC | $6.9M | 3.25% |
| 15 | MRUS MERUS N V | $6.6M | 3.13% |
| 16 | DNTH DIANTHUS THERAPEUTICS INC | $6.0M | 2.83% |
| 17 | HLXB HELIX ACQUISITION CORP II | $5.3M | 2.47% |
| 18 | UPB UPSTREAM BIO INC | $4.9M | 2.32% |
| 19 | CNTX CONTEXT THERAPEUTICS INC | $4.9M | 2.32% |
| 20 | VYGR VOYAGER THERAPEUTICS INC | $4.7M | 2.21% |
Values as reported on the Q4 2024 Form 13F. Every position is in the holdings table below.